I'm not saying that's true. I'm saying that's something a 3-arm trial could address. We have at least the anecdotes from Dr. D's case as a hint that might be true. And forgive me if I misquote Ohm, but I believe he/she said that checkpoint inhibitors method of action is something Leronlimab would accomplish by itself, rendering them superfluous and thus avoiding the checkpoint inhibitors' side effects, which are not negligible.